Clinical Trials on Diffuse Cerebral Sclerosis of Schilder
Total 3908 results
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisFrance, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisKorea, Republic of, Taiwan, Czechia, Japan, Poland
-
Eli Lilly and CompanyCompletedRelapsing-Remitting Multiple SclerosisHungary, United States, France, Ukraine, Poland, Germany, Israel, Russian Federation, Czechia, Serbia, Romania, Slovakia, Bulgaria
-
BiogenAbbVieCompletedRelapsing-Remitting Multiple SclerosisGermany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
-
Nantes University HospitalCompletedRelapsing-remitting Multiple SclerosisFrance
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisGermany
-
Universita di VeronaCompletedRelapsing-Remitting Multiple SclerosisItaly
-
BiogenAbbVieCompletedRelapsing-Remitting Multiple SclerosisCzech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
-
BiogenAbbVieCompletedRelapsing-Remitting Multiple SclerosisSweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisItaly
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisBelgium, Bulgaria, Canada, Croatia, Czech Republic, Finland, Germany, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
-
Claudio GobbiOspedale Civico, LuganoCompletedRelapsing-remitting Multiple SclerosisSwitzerland
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Claudio GobbiBayerTerminatedRelapsing-remitting Multiple SclerosisSwitzerland
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.A.S, FranceCompletedMultiple Sclerosis, Relapsing, Remitting
-
Coordinación de Investigación en Salud, MexicoCompleted
-
NovartisCompletedEfficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (FREEDOMS)Relapsing-remitting Multiple SclerosisCanada, Australia, Israel, Belgium, Czech Republic, Finland, France, Germany, Greece, Lithuania, Netherlands, Poland, Russian Federation, Slovakia, South Africa, Sweden, Switzerland, Turkey, United Kingdom
-
Universita di VeronaCompletedRelapsing-remitting Multiple SclerosisItaly
-
University Hospital Inselspital, BernePharmaPart; Viollier AG, Basel, SwitzerlandCompletedRelapsing-remitting Multiple SclerosisSwitzerland
-
Cantonal Hospital of St. GallenUnknownRelapsing-Remitting Multiple SclerosisSwitzerland
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisFinland
-
NeurognosticsCompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenCompletedRelapsing Forms of Multiple SclerosisUnited States
-
EMD SeronoCompletedRelapsing Multiple SclerosisUnited States
-
BayerWithdrawnMultiple Sclerosis, Relapsing-RemittingKorea, Republic of
-
Swiss Federal Institute of TechnologyKliniken Valens, Rehazentrum Valens, Taminaplatz 1, 7317 ValensCompletedAssessment of Arm and Hand Sensorimotor Functions in Multiple Sclerosis SubjectsSwitzerland
-
University of California, Los AngelesRecruitingPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University College DublinCompletedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisIreland
-
Innate ImmunotherapeuticsNational Multiple Sclerosis Society; Primorus Clinical TrialsCompletedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisNew Zealand
-
Canadian Scleroderma Research GroupCanadian Institutes of Health Research (CIHR)UnknownSystemic Sclerosis | Small Intestinal Bacterial OvergrowthUnited States, Australia
-
Assiut UniversityCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedRaynaud Phenomenon Secondary to Systemic SclerosisFrance
-
Imperial College LondonGlaxoSmithKline; University College, London; Medical Research Council; Queen Mary... and other collaboratorsCompletedRelapsing-remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
University Hospital, MontpellierGenzyme, a Sanofi CompanyTerminatedProgressive Multiple Sclerosis | Multiple Sclerosis, Relapsing-RemittingFrance
-
Novartis PharmaceuticalsCompletedRelapsing Remitting Multiple Sclerosis RRMSGermany, Switzerland
-
Novartis PharmaceuticalsTerminatedRelapsing-remitting Multiple Sclerosis (RRMS)United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenCompletedFatigue | Relapsing-Remitting Multiple SclerosisSweden, Norway, Austria, Denmark
-
GE HealthcareCentre for Probe Development and CommercializationCompletedRelapsing-remitting Multiple Sclerosis (rrMS)Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | RRMSRussian Federation, Ukraine, Czech Republic
-
ActelionCompletedRaynaud's Phenomenon Secondary to Systemic SclerosisGermany, France, United Kingdom
-
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences...CompletedRaynaud's Phenomenon Secondary to Systemic SclerosisUnited States
-
Seoul National University HospitalTerminatedSystemic Sclerosis | Raynaud Disease | Digital UlcerKorea, Republic of
-
Novartis PharmaceuticalsCompletedMultiple Sclerosis | Relapsing Multiple Sclerosis | Advancing Multiple SclerosisUnited States, Puerto Rico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingMultiple Sclerosis | Remitting Relapsing Multiple SclerosisFrance
-
University Hospital, MontpellierRecruiting
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRecruiting
-
University of LouisvilleRecruitingRelapsing Remitting Multiple SclerosisUnited States